Skip to main content
. 2017 Jul 26;135(2):307–315. doi: 10.1007/s11060-017-2575-9

Table 1.

Baseline characteristics

Patient ID Age at diagnosis (years) Gender Histology Encasement a. Basilaris Ring enhancement Metastases Symptom duration (weeks) Dexa use Risk group Study cohort
1 17.3 F Anaplastic Astrocytoma (WHO III) 181 < encasement < 360° Yes No 4 No High 1
2 11.8 M n.a. 181 < encasement < 360° Yes No 2 Yes High 1
3 11.2 M Glioblastoma (WHO IV) 181 < encasement < 360° Yes No 1.5 Yes High 1
4 10.8 M n.a.a 181 < encasement < 360° No No 4 Single dose Intermediate 2
5 12.4 F Glioblastoma (WHO IV) Full (360°) No No 0.5 Yes Intermediate 2
6 7.5 M Astrocytoma (WHO II) 181 < encasement < 360° No No 2 No Intermediate 2
7 7.6 F n.a. 181 < encasement < 360° Yes No 3 No High 3
8 7.7 M n.a. Full (360°) No No 2 No Intermediate 3
9 9.9 F n.a. Full (360°) Yes No 1 Yes High 3
Median 10.8 2.0

n.a. not applicable, meaning no biopsy performed

aBiopsy performed, inconclusive results